Columnists

Tim Boreham: Sperm sorter Memphasys is finding its feet as a grower, not a shower

November 26, 2018November 26, 2018 | Tim Boreham

HEAR IT FIRST WITH OUR DAILY NEWSLETTER

Email Lists
Morning Update
Lunch Update

Subscribe

We don't spam. Learn more about our Privacy Policy

Columnists

Tim Boreham: what’s next for stem cell play Regeneus as it waits for Japan deal

November 19, 2018November 18, 2018 | Tim Boreham

Columnists

Allegra hops closer to implanting kangaroo tendons in people

November 14, 2018November 15, 2018 | Tim Boreham

Columnists

Blood bank Cryosite’s cash balance is bigger than its market cap

November 5, 2018November 5, 2018 | Tim Boreham

Columnists

Here’s what’s next for biotech dazzler Biotron

October 29, 2018October 29, 2018 | Tim Boreham

Columnists

How ex-ASX biotech Redhill became the one that got away

October 22, 2018October 22, 2018 | Tim Boreham

Columnists

Novita gets ready for US launch of attention deficit disorder tool

October 15, 2018October 15, 2018 | Tim Boreham

Columnists

What’s next for high-tech nappy maker Simavita

October 8, 2018October 8, 2018 | Tim Boreham

Columnists

Tim Boreham: here are a dozen ASX stocks that show sport and drugs do mix

October 1, 2018October 1, 2018 | Tim Boreham

Columnists

What’s next for high-flying dodgy knee fixer Paradigm Biopharma

September 24, 2018September 24, 2018 | Tim Boreham